Keratoacanthoma - Keratoakantomo
☆ En la 2022 Stiftung Warentest rezultoj de Germanio, konsumanto kontento kun ModelDerm estis nur iomete pli malalta ol kun pagitaj telemedicinaj konsultoj.
Tipa Keratoakantomo (Keratoacanthoma)
References
Keratoacanthoma (KA) estas ofta haŭta tumoro konata pro sia rapida kresko kaj potencialo regresi memstare. Ĝi tipe okazas en pli maljunaj, helhaŭtaj viroj kun historio de sundamaĝo. Dum kirurgia forigo uzante detranĉon aŭ Mohs-mikrografan kirurgion estas la kutima traktado, ekzistas diversaj aliaj terapiopcioj haveblaj.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) estas malaltgrada tumoro kiu komenciĝas en certaj glandoj en la haŭto kaj aspektas simila al squamous cell carcinoma (SCC) sub mikroskopo. Estas daŭra debato pri ĉu KA devus esti klasifikita kiel formo de enpenetra SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) estas la dua plej ofta tipo de kancero en homoj, precipe inter pli maljunaj individuoj. Kirurgio estas kutime uzata por trakti cSCC, sed por iuj pacientoj, kiuj ne povas kirurgion aŭ elektas ne fari, aliaj opcioj kiel intraleziaj traktadoj povas esti konsiderataj. Tradiciaj intraleziaj traktadoj (methotrexate or 5-fluorouracil) estis uzitaj, sed ekzistas daŭra esplorado pri novaj aliroj kiel intralezia imunoterapio kaj onkoliza viroterapio. Ĉi tie, ni rigardos malsamajn intraleziajn traktadojn por cSCC, intervalante de klasikaj metodoj ĝis avangardaj strategioj.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Sub la mikroskopo, keratoakantomo (keratoacanthoma) tre proksime similas skvamĉelan karcinomon. Dum kelkaj patologoj klasifikas keratoakantomo (keratoacanthoma) kiel klaran unuon kaj ne malignecon, proksimume 6% de klinikaj kaj histologiaj keratoakantomo (keratoacanthoma) progresas al enpenetraj kaj agresemaj skvamaj kanceroj.
○ Diagnozo kaj Traktado
#Dermoscopy
#Skin biopsy